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Abstract Recently we discovered that a naturally occurring
C-terminally truncated thioredoxin (Trx80) is a potent mitogen-
ic cytokine stimulating IL-12 production from CD40+ mono-
cytes. To further characterise Trx80 we have engineered cys-
teine to serine mutants of Trx80 corresponding to the active site
cysteines of Trx (Trx80SGPS) and to the structural cysteine at
position 72 (Trx80C72S). Trx80SGPS and Trx80C72S re-
tained the cell stimulatory activity of Trx80 and increased pe-
ripheral blood mononuclear cell (PBMC) proliferation three-
to ¢ve-fold in vitro (P6 0.01, n=18). Both Trx80SGPS and
Trx80C72S signi¢cantly stimulated IL-12 and IFN-Q secretion
from PBMCs in the same manner as Trx80 (P6 0.01, n=9 and
10). The previously described Trx80 dimer is caused by non-
covalent interactions, and not by any intermolecular disulphide
bonds.
5 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Human cytosolic thioredoxin (Trx) is in its dithiol form the
major intracellular disulphide reductase. Reduced Trx is not
only an electron donor to many proteins but can also regulate
the activity of other proteins by thiol redox control [1^3].
When cells are activated by various stimuli, Trx translocates
from the cytoplasm to the nucleus [3^8]. In the nucleus, Trx
regulates DNA binding and activity of transcription factors,
such as AP-1, NF-UL and glucocorticoid receptor [3,9^18].
Reduced Trx binds to the MAPKKK apoptosis signalling ki-
nase 1 (ASK1). Binding of reduced Trx to ASK1 inhibits
ASK1, thus preventing apoptosis [19]. Extracellular Trx is a
co-cytokine with several interleukins, like IL-1, IL-4, IL-6 and
TNF-K [12,20,21]. Plasma levels of Trx are increased in cer-
tain diseases where the immune system is involved, for exam-
ple in HIV and rheumatoid arthritis [22,23]. Increased Trx
plasma levels in HIV correlates with a shorter life-expectancy
for the a¡ected patient. It has been proposed that this is
caused by the fact that extracellular Trx is a chemokine for
T cells, monocytes and PMN cells [24^26].
In addition, an extracellular C-terminally truncated version
of Trx was detected in human peripheral blood mononuclear
cell (PBMC) cultures, in which monocytes were the major
cellular source [27^32]. Truncated Trx stimulates eosinophilic
cell cytotoxicity, an e¡ect that Trx lacks. Moreover, truncated
Trx lacks the capacity to catalyse dithiothreitol (DTT) reduc-
tion of insulin disulphides, which is a hallmark for Trx [32,33].
Recombinant truncated Trx with the 80 N-terminal residues
(Trx80) has the same e¡ects on eosinophilic cytotoxicity com-
pared to endogenously puri¢ed truncated Trx. Moreover,
Trx80, like endogenous truncated Trx, lacks redox activity
with insulin-disulphides [32].
We have earlier described that human plasma levels of trun-
cated Trx vary to a large degree between di¡erent individuals.
In 12 donors levels of truncated Trx were between 1 and 171
ng/ml, with a median value of 20 ng/ml [33]. High expression
of truncated Trx was found at the cell membrane of mono-
cytes when sub-cellular localisation of truncated Trx was eval-
uated in several di¡erent cell lines [34]. Trx80 induces prolif-
eration of human PBMCs and the primary target cell for
Trx80 in PBMC cultures is the monocyte. Trx80 stimulates
a Th1 response in human PBMC cultures by inducing secre-
tion of the Th1 inducer cytokine IL-12 from CD40þ mono-
cytes. Trx80 also plays a possible role in innate immunity
since monocytes stimulated with 100 nM Trx80 up-regulate
their CD14 receptor ¢ve-fold. Moreover, Trx80 up-regulates
CD40, C54 and CD86 on monocytes, an e¡ect that Trx lacks.
In addition, Trx80 stimulates IFN-Q secretion in synergy with
IL-2 in PBMC cultures [33,35]. We have shown that Trx80 is
a dimer in solution, with a secondary structure that resembles
Trx measured by circular dichroic spectroscopy [33].
Since Trx80 possesses unique cell stimulatory functions on
monocytes we examined if the function of Trx80 is dependent
on oxido-reductase activity. Previous results showing that
Trx80 is not a substrate for Trx reductase (TrxR) in vitro
and does not catalyse insulin disulphide reduction by DTT
[32,33] led us to believe that the function of Trx80 could be
di¡erent from Trx and not dependent on thiol^disulphide ex-
change reactions. In order to further investigate how Trx80
exerts its cell stimulatory e¡ects we performed site-directed
mutagenesis of the active site cysteines, Cys31 and Cys34,
and the structural cysteine at position 72 in Trx80 replacing
these Cys residues with Ser residues. In cell experiments with
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human PBMCs we found that Trx80SGPS and Trx80C72S
retained the cytokine properties of Trx80. Moreover, we
found that Trx is able to reduce both Trx80 and Trx80C72S
but not Trx80SGPS and that the Trx80 dimer is held together
by non-covalent forces.
2. Materials and methods
2.1. Materials
AIM V cell culture medium and L-glutamine were purchased from
Life Technologies, Paisley, UK; isopropyl thiogalactoside was from
Saveen Biotech, Malmo«, Sweden; primers were provided by Kebo
Lab, Stockholm, Sweden; Nco 1 and Sal 1 were purchased from
Promega, Madison, WI, USA; Ficoll^Paque and [3H]thymidine
were from Amersham Pharmacia Biotech, Uppsala, Sweden; Poly-
myxin B sulphate was provided by Sigma Chemical, St. Louis, MO,
USA; Spin-X ¢lters were from Corning Costar, Cambridge, MA,
USA; penicillin/streptomycin were purchased from Bio Whittaker Eu-
rope, Verviers, Belgium; IL-12 (p40 and p70 reactive) and IFN-Q
sandwich enzyme-linked immunosorbent assay (ELISA) antibodies,
human recombinant IL-12 and alkaline phosphate-linked streptavidin
were from Mabtech, Nacka, Sweden; human recombinant IFN-Q was
from PreproTech, London, UK; IL-18 sandwich ELISA antibodies
and human recombinant IL-18 were provided by RpD Systems, Min-
neapolis, MN, USA.
2.2. Construction and puri¢cation of C31S, C34S Trx80 mutant named
Trx80SGPS
In order to introduce the cysteine to serine mutations of the active
site cysteines at positions 31 and 34 of Trx80 two oligonucleotides
were synthesised having the sequences 5P-GCC ACG TGG TCT
GGG CCT TCC AAA ATG ATC AAG CC 3-P and 5P-GG CTT
GAT CAT TTT GGA AGG CCC AGA CCA CGT GGC 3-P, with
the underlined nucleotides introducing the desired point mutations. A
polymerase chain reaction (PCR) was run with pET 3d/Trx80 [33] as
template using 25 cycles of 95‡C 1 min, 55‡C 1 min, and 68‡C 12 min.
The resulting PCR product was puri¢ed and ligated into a pGEM T
vector. This was transformed to Escherichia coli strain DH-5K, am-
pli¢ed and the sequence was veri¢ed using an ALF DNA sequenator
(Pharmacia, Uppsala, Sweden). The pGEM T vector insert carrying
the active site mutant of Trx80 was then cut with restriction enzymes
Nco 1 and Sal 1 and subsequently ligated to a pET 24d expression
plasmid. The resulting pET 24d-Trx80SGPS expressed in an E. coli
BL-21 (DE3) strain, grown in Luria^Bertani (LB) medium containing
30 Wg/ml kanamycin at 37‡C to an optical density of 0.5 at 595 nm
and induced with 0.5 mM isopropyl thiogalactoside. Cells were har-
vested after 4 h and the Trx80SGPS protein was then puri¢ed using
the same puri¢cation scheme as described earlier for Trx80 [33].
2.3. Construction and puri¢cation of the Trx80C72S mutant
A PCR was run with pACA/Trx-C72S [36] as template with the
same oligonucleotides used when designing recombinant Trx80 [33].
The resulting PCR product was puri¢ed and ligated into a pGEM T
vector, transformed into E. coli DH-5K strain, ampli¢ed and subse-
quently the sequence was veri¢ed using an ALF DNA sequenator
(Pharmacia). The pGEM T vector with the Trx80C72S insert was
subsequently cut with Nco 1 restriction enzyme and ligated into a
pET 24d expression plasmid. The pET 24d-Trx80C72S plasmid was
transformed to E. coli BL-21 (DE3) strain, grown in LB medium,
induced and puri¢ed as described above.
The Trx80SGPS and Trx80C72S were pure when run on an 8^25%
gradient sodium dodecyl sulphate (SDS)-gel and silver-stained (Fig.
1). Protein concentrations of Trx80, Trx80SGPS and Trx80C72S were
estimated as described before [33]. Trx was over-expressed and puri-
¢ed as described before [36].
2.4. SDS^polyacrylamide gel electrophoresis (PAGE)
Trx, Trx80, Trx80SGPS and Trx80C72S were kept at 25^45 WM in
phosphate-bu¡ered saline (PBS) bu¡er at room temperature overnight
to allow oxidation [36]. Subsequently, one set of protein samples was
incubated at 95‡C with a loading bu¡er containing SDS and DTT,
whereas the other set of protein samples was incubated with a loading
bu¡er lacking DTT. This procedure was performed to investigate if
SDS and heating alone would make the proteins appear as monomers
on the gel, showing that the dimer of Trx80 is caused by non-covalent
forces, or if DTT was needed to make the proteins monomeric, sug-
gesting that the Trx80 dimer is held together by intermolecular disul-
phide bonds, which are not accessible to DTT when the protein is
folded [33]. Protein samples were run on an 8^25% gradient SDS-gel
on a Phastsystem (Pharmacia LKB, Uppsala, Sweden) and subse-
quently silver-stained (Fig. 1).
2.5. Enzymatic assays
The reduced nicotinamide adenine dinucleotide phosphate
(NADPH) consumption assay was carried out at 20‡C in a total
volume of 500 Wl with 200 WM NADPH in TE bu¡er. The reaction
cuvette contained 10 WM of either oxidised Trx80, Trx80SGPS or
Trx80C72S. The reaction was initiated by adding 10 Wg of calf thymus
TrxR to both the reference and reaction cuvettes, and A340 nm was
recorded. This was followed by addition of 1 WM Trx to both the
reference and reaction cuvettes, and NADPH consumption was fol-
lowed at 340 nm using an Ultrospecz 3000 spectrophotometer
(Amersham-Pharmacia Biotech) [37]. Trx80, Trx80SGPS and
Trx80C72S were also tested for their ability to catalyse DTT reduc-
tion of insulin disulphides [38].
2.6. Cell experiments
Human PBMCs were puri¢ed from healthy blood donors (Blood
Bank, Karolinska Hospital) by standard Ficoll^Paque centrifugation.
The puri¢ed PBMCs were resuspended at 1U106 cells/ml in serum-
free AIM V medium supplemented with 2 mM L-glutamine, penicillin
at 100 units/ml and streptomycin at 100 Wg/ml for all cell experiments.
All cell experiments were performed at 37‡C and 5% CO2 in a hu-
midi¢ed cell incubator. Before addition to cell cultures Trx80,
Trx80SGPS and Trx80C72S were passed over a column with poly-
myxin B-linked agarose according to the manufacturer’s recommen-
dation to remove any possible endotoxin contamination, and subse-
quently reduced with excess DTT, desalted and sterile-¢ltered.
The [3H]thymidine assays were performed in 96-well £at-bottomed
plates for 3 days in a ¢nal volume of 200 Wl. Cells were stimulated
with Trx80, Trx80SGPS, Trx80C72S or Trx at concentrations from 10
nM to 1 WM, IL-2 at 5 U/ml or 20 U/ml. 9 h prior to terminating the
cultures each well was pulsed with 0.5 WCi of [3H]thymidine. Cells
were then harvested onto ¢bre-glass ¢lters using a multi-channel cell
harvester (Tomtec, Wallac) and counted with a MicroBeta Plus Scin-
tillation counter (Tomtec, Wallac).
PBMC cultures that were assayed for IL-12 and IFN-Q production
were grown in 24- or 48-well £at-bottomed plates for 3 days at 1U106
cells/ml in serum-free AIM V medium supplemented as described
above. PBMC cultures assayed for IL-18 were cultured for 1, 2 and
3 days. All cell cultures which were assayed for cytokine production
were in a ¢nal volume of 500 Wl to 1 ml. Cells were cultured in the
presence of Trx80, Trx80SGPS, Trx80C72S or Trx at 100 nM or 1 WM
with or without IL-2 at 20 U/ml or with only IL-2 at 20 U/ml. When
terminating cultures cells were centrifuged 400Ug for 10 min and
supernatants were collected in three di¡erent aliquots and immedi-
ately frozen at 320‡C. Cell medium was then analysed in duplicate
wells using sandwich ELISA for IL-12, IL-18 and IFN-Q. The sand-
wich ELISA for IL-12 detected both IL-12 heavy chain (p40) and the
heterodimer (p70). The detection limit of the IL-12 ELISA was 0.2 ng/
ml; IL-18 ELISA, 0.3 ng/ml; and for IFN-Q ELISA the detection limit
was 0.03 ng/ml.
2.7. Statistics
[3H]thymidine incorporation and cell medium levels of cytokines in
PBMC cultures were compared using the non-parametric Wilcoxon
matched-pairs test. A P value of less than 0.05 was considered statis-
tically signi¢cant.
3. Results
3.1. Enzymatic activity of Trx80, Trx80SGPS and Trx80C72S
Trx80, Trx80SGPS and Trx80C72S did not act as sub-
strates for TrxR (Fig. 2). However, when 1 WM of Trx was
added both to the reaction cuvettes and the reference cuvette
a change in absorbance at 340 nm was seen in cuvettes con-
taining Trx80 and Trx80C72S. Hence, as shown in Fig. 2, Trx
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was able to reduce disulphides in Trx80 and Trx80C72S in a
similar way as described earlier for Trx reduction of Trx80
[33]. However, Trx was not able to reduce disulphides in
Trx80SGPS (data not shown). This indicates that the disul-
phide that Trx reduces in oxidised Trx80 is located between
Cys31 and Cys34.
3.2. Characterisation of the Trx80 dimer
Upon Sephadex G-75 chromatography with 1 mM DTT
present, reduced Trx80 eluted before Trx with an Mr of
25 000, demonstrating that Trx80 is a dimer in solution [33].
Supradex75 chromatography of Trx, Trx80, Trx80C72S and
Trx80SGPS under the same conditions as above gave similar
results and Trx80, Trx80C72S and Trx80SGPS all eluted with
an Mr of 25 000. However, in contrast to Trx80C72S and
Trx80, Trx80SGPS also showed higher molecular weight spe-
cies, indicating aggregation (data not shown). To further elu-
cidate the characteristics of the Trx80 dimer we performed
reducing and non-reducing gel electrophoresis of oxidised
Trx80, Trx80C72S, Trx80SGPS and Trx. Trx formed a dimer
upon oxidation as described before [36]. This dimer was resis-
tant to heating and SDS treatment but not to DTT, showing
that it was held together by a disulphide bond (Fig. 1). The
fact that Trx upon oxidation forms an intermolecular disul-
phide between Cys72 has been described earlier [36,39]. In
contrast, the dimer of Trx80, Trx80C72S and Trx80SGPS
seen upon gel ¢ltration [33] was not resistant to SDS and
heating. This shows that the dimer was held together by
non-covalent interactions (Fig. 1). These are probably hydro-
phobic interactions, as suggested before [33]. The addition of
DTT did not change the result for Trx80 and Trx80C72S.
However, the aggregation seen on gel ¢ltration and on non-
reducing SDS^gel electrophoresis for Trx80SGPS disappeared
when the Trx80SGPS sample was treated with DTT and in-
cubated at 95‡C in the presence of SDS (Fig. 1).
3.3. Trx80SGPS and Trx80C72S have the same e¡ect on cell
proliferation as Trx80
Human PBMCs were cultured in serum-free AIM V me-
dium in the presence of Trx80, Trx80C72S, Trx80SGPS or
Trx at 10 nM to 1 WM for 3 days (Fig. 3). At 100 nM and
1 WM Trx80 gave a median three-fold increase in DNA syn-
thesis measured by [3H]thymidine incorporation (P6 0.01,
n=18 for 100 nM and P6 0.05, n=8 for 1 WM). The mutants
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Fig. 1. SDS^gel electrophoresis of Trx, Trx80, Trx80C72S and
Trx80SGPS under reducing and non-reducing conditions. Trx,
Trx80, Trx80SGPS and Trx80C72S were oxidised overnight at room
temperature at 25^45 WM in PBS. Proteins were then incubated in
2% SDS bu¡er with and without 10 mM DTT at 95‡C. Subse-
quently, protein samples were loaded upon an 8^25% gradient
SDS^PAGE and silver-stained. As indicated in the ¢gure, Trx forms
a disulphide-linked dimer upon oxidation. In contrast, Trx80,
Trx80C72S and Trx80SGPS dimers seen upon gel ¢ltration are bro-
ken by SDS treatment, indicating that the dimer forms by non-co-
valent interactions.
Fig. 2. Reduction of Trx80 and Trx80C72S by Trx, NADPH and
TrxR. Both reference and reaction cuvettes contained TE bu¡er
with 200 WM NADPH. To the respective reaction cuvettes 10 WM
of Trx80, Trx80C72S and Trx80SGPS was added. Reactions were
then initiated by adding 10 Wg of TrxR to both the reference and
reaction cuvettes. Absorbance at 340 nm was recorded. At the time
point indicated with an arrow, 1 WM of Trx was added to each cu-
vette. Time-dependent consumption of NADPH when Trx is reduced
by TrxR and recycles by reducing Trx80 and Trx80C72S is illus-
trated by changes of absorbance at 340 nm; (E) indicates Trx80;
(R) indicates Trx80C72S.
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Fig. 3. Trx80, Trx80SGPS and Trx80C72S induce proliferation in
PBMCs. Human PBMCs at 1U106 cells/ml were cultured in the
presence of di¡erent concentrations of Trx80, Trx80SGPS, Trx80C72S,
Trx, as indicated in the ¢gure, or IL-2 at 5 U/ml in AIM V medium
for 3 days. 9 h prior to harvesting cultures 0.5 WCi [3H]thymidine
was added. The mean of [3H]thymidine incorporation from triplicate
wells in one representative donor of 18 is shown. There was a sig-
ni¢cant increase in proliferation when cells were cultured in the
presence of 100 nM or 1 WM Trx80, Trx80SGPS and Trx80C72S,
or IL-2 at 5 U/ml compared to unstimulated cells. * =P6 0.05;
**=P6 0.01 (n=18).
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Trx80SGPS and Trx80C72S also had their maximum e¡ect at
100 nM (P6 0.01, n=18), and their stimulation of DNA syn-
thesis was similar compared to Trx80. The increase in DNA
synthesis by Trx80 and the mutants at 100 nM were approx-
imately the same as for 5 U/ml of IL-2. Trx gave no e¡ect on
cell proliferation (Fig. 3).
3.4. Trx80, Trx80SGPS and Trx80C72S induce secretion of
IL-12 and IFN-Q in human PBMCs
Trx80, Trx80SGPS and Trx80C72S all induced secretion of
IL-12 from human PBMCs cultured in serum-free AIM V
medium for 3 days (Fig. 4). In unstimulated cells, or in cells
cultured in the presence of Trx at 100 nM or 1 WM and/or
IL-2 at 20 U/ml, IL-12 was not detected. Trx80, Trx80SGPS
and Trx80C72S at 1 WM gave a signi¢cant increase in IL-12
secretion (P6 0.05 for Trx80 and P6 0.01 for Trx80SGPS
and Trx80C72S, n=9) (Fig. 4). The levels of IL-12 varied
among the di¡erent donors between 0.2 and 2 ng/ml measured
by sandwich ELISA. When Trx80 and the mutant proteins
were cultured together with IL-2 at 20 U/ml an enhanced
e¡ect was seen and 1 WM of either Trx80, Trx80SGPS or
Trx80C72S cultured in combination with 20 U/ml of IL-2
gave IL-12 levels of 0.2^15 ng/ml in the di¡erent donors
(P6 0.01, n=9; Fig. 4). Also, Trx80, Trx80SGPS and
Trx80C72S at 100 nM in combination with IL-2 at 20 U/ml
gave a signi¢cant increase in IL-12 secretion (P6 0.05 for
Trx80 an P6 0.01 for Trx80SGPS and Trx80C72S, n=10;
Fig. 4).
Neither Trx80 nor Trx80SGPS, Trx80C72S, Trx or IL-2
could induce secretion of IFN-Q from PBMCs cultured in
serum-free AIM V medium for 3 days (Fig. 5). However,
when PBMCs were cultured in the presence of both IL-2 at
20 U/ml and Trx80, Trx80SGPS or Trx80C72S at 100 nM or
1 WM a synergistic e¡ect on IFN-Q secretion was seen (Fig. 5).
This e¡ect was not seen when PBMCs were cultured with Trx
and IL-2 in combination (Fig. 5). The e¡ect of all three Trx80
proteins was similar on IFN-Q secretion and the absolute IFN-
Q values in di¡erent donors varied between 5 and 40 ng/ml
when cultured in the presence of 20 U/ml IL-2 and Trx80 or
mutant Trx80 at 1 WM (P6 0.01 for all proteins, n=9 for
Trx80C72S and n=10 for Trx80 and Trx80SGPS). Also,
Trx80, Trx80SGPS and Trx80C72S at 100 nM in combination
with 20 U/ml of IL-2 gave a signi¢cant increase in IFN-Q
secretion, being between 0 and 12 ng/ml in di¡erent donors
(P6 0.01 for all proteins, n=10 for Trx80SGPS and n=9 for
Trx80 and Trx80C72S; Fig. 5).
Trx80, Trx80 SGPS, TrxC72S or Trx alone or in combina-
tion with IL-2 did not stimulate secretion of IL-18 in PBMC
cultures (data not shown).
4. Discussion
In this study we have conclusively shown that the mecha-
nism of the mitogenic cytokine Trx80 does not depend on the
active site Cys residues of Trx, since the mutant protein
Trx80SGPS showed the same e¡ects as Trx80 in stimulating
PBMC proliferation and IL-12 and IFN-Q production in
PBMC cultures (Figs. 3^5). This is a surprising result since
for all described e¡ects of Trx as an extracellular co-cytokine
and chemokine the Cys residues and the associated oxido-
reductase activity of the protein are essential [3,26]. In addi-
tion, when Trx modulates intracellular signalling pathways by
activating transcription factors and Jun N-terminal kinase or
inactivating the MAPKKK ASK1, the active site Cys residues
are essential [3,8,16,17,40,41].
Trx80 was previously shown to lack disulphide reductase
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Fig. 5. Trx80, Trx80SGPS and Trx80C72S in synergy with IL-2 in-
duce secretion of IFN-Q. Human PBMCs at 1U106 cells/ml were
cultured in AIM V medium for 3 days in the presence of Trx80,
Trx80SGPS, Trx80C72S and Trx at 100 nM and 1 WM alone or in
combination with IL-2 at 20 U/ml as indicated in the ¢gure. IFN-Q
secreted to the medium was analysed in duplicate wells with sand-
wich ELISA. One representative experiment out of nine is shown.
There was a signi¢cant increase in the treatment indicated with
*=P6 0.05 and **=P6 0.01 (n=9) compared to unstimulated
cells. The detection limit of the ELISA was 0.03 ng/ml of IFN-Q.
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Fig. 4. Trx80, Trx80SGPS and Trx80C72S induce secretion of IL-12
from PBMCs. Human PBMCs at 1U106 cells/ml were cultured in
AIM V medium for 3 days in the presence of Trx80, Trx80SGPS,
Trx80C72S and Trx at 100 nM and 1 WM, with or without IL-2 at
20 U/ml or in the presence of only IL-2 as indicated in the ¢gure.
IL-12 secreted to the medium was analysed in duplicate wells with
sandwich ELISA. The ¢gure shows the median result of nine experi-
ments with di¡erent blood donors. There was a signi¢cant increase
in the treatments indicated with *=P6 0.05 and **=P6 0.01 com-
pared to unstimulated cells. The detection limit of the ELISA was
0.2 ng/ml of IL-12.
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activity with insulin [32,33], which is a test of general dithiol^
disulphide oxido-reductase activity of Trx. However, Trx was
able to reduce disulphides in Trx80 and we speculated that
this interaction could occur at the cell surface and mediate the
cytokine activities of Trx80 [33,35]. Here we show that Trx
reduces disulphides in Trx80 and Trx80C72S but not in
Trx80SGPS (Fig. 2), although all three Trx80 proteins show
the same cytokine e¡ects on PBMCs (Figs. 3^5). Hence, this
study does not support the earlier suggested mechanism of
Trx80, involving thiol^disulphide exchange reactions between
Trx80 and Trx at the cell surface, and instead suggests that
the mechanism whereby Trx80 exerts its cytokine e¡ects is
redox-independent.
It is known that human Trx upon oxidation forms dimers
with intermolecular disulphides involving Cys72 [36,39]. How-
ever, this intermolecular disulphide is reduced when DTT is
present [36]. We have previously shown that Trx80 is a dimer
in solution also in the presence of DTT and we proposed that
upon truncation of Trx to Trx80 a hydrophobic surface area
should be exposed that causes the dimer formation of Trx80
[33]. Moreover, we have seen that Trx80SGPS, Trx80C72S
and Trx80 have similar elution pro¢les upon gel chromatog-
raphy with 1 mM DTT, eluting before Trx with a Mr of
25 000. The ¢nding that the Trx80 dimer is broken upon treat-
ment with SDS and heating supports the idea that the dimer is
held together by hydrophobic interactions rather than cova-
lent intermolecular bonds (Fig. 1).
Trx80, Trx80SGPS and Trx80C72S have the same activity
when stimulating IFN-Q secretion. In PBMCs the main cellu-
lar source of IFN-Q are the T cells. We have previously shown
that Trx80 does not stimulate the T cells directly. Trx80 ¢rst
stimulates IL-12 production from monocytes, which in turn
presumably induces IFN-Q secretion from T cells [35]. In ad-
dition, it is clear that IL-2 is a more potent inducer of PBMC
proliferation compared to Trx80 (Fig. 3). However, Trx80 is
superior to IL-2 in inducing IL-12 secretion (Fig. 4). The
e¡ects of Trx80 on PBMC proliferation are probably caused
by two mechanisms. Firstly, Trx80 directly stimulates prolif-
eration of puri¢ed monocytes [35]. Secondly, the secretion of
IL-12 from CD40þ monocytes will induce proliferation of
T cells in the PBMC cultures. However, IL-12 is less potent
compared to IL-2 in inducing T cell proliferation [35,42].
The data that have accumulated around Trx80 raise several
important issues. The in vitro [43,44] studies suggest that
Trx80 can be important in: (i) protecting monocytes from
apoptosis and promoting phagocytosis of apoptotic cells by
monocytes by enhancing the expression of the CD14 receptor;
and (ii) inducing a Th1-type immune response in T cells by
stimulating IFN-Q and IL-12 production [35,45^48]. These ef-
fects should be important for the individual to clear viral
infections, but could also be harmful by eliciting autoimmune
responses [49].
Since we have now shown that Trx80 exerts its e¡ects via a
mechanism independent of thiol^disulphide reactions we pro-
pose that the e¡ects of Trx80 are receptor-mediated. The re-
ceptor is probably located at the cell surface on monocytes
since Trx80 mediates its e¡ects via monocytes and since trun-
cated Trx is localised at the cell surface on monocytes
[31,32,34,35]. The e¡ects of Trx80 are unique and important
in pathophysiology, and therefore it is of great importance to
further elucidate the identity of a possible receptor for Trx80
and the mechanism by which Trx80 is produced.
The great variation of Trx80 levels in apparently healthy
blood donors should also be elucidated, and this might be a
prognostic factor for the risk to develop certain autoimmune
diseases such as rheumatoid arthritis and diabetes.
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